Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” second quarter 2025 investor ...

Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” second quarter 2025 ...

Becton Dickinson (BDX) recently announced the initiation of a pharma-sponsored clinical trial featuring their BD Libertas Wearable Injector, alongside an affirmed quarterly dividend and leadership ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A and why I remain bullish on BDX.

Becton, Dickinson and Company is an attractive firm that just made a good deal. Click here to find out why BDX stock is a Buy.

Any one of the majors will be thrilled to snap some of these brands because there’s very little organic growth in the ...

New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) ...

Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for around $17.5 ...

This was the stock's second consecutive day of losses.

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

Becton, Dickinson and Company (NYSE:BDX) is a medical device company that develops and manufactures medical supplies, devices, laboratory equipment, and diagnostic products.